Companies › Galimedix Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GAL-101 | – | Phase 2 | Geographic Atrophy of the Macula | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06659549 | GAL-101 | Phase 2 | Geographic Atrophy of the Macula | Ophthalmology | Mar 2027 |
No annotated target.
–
Vantage Biosciences Tourmaline Bio, Inc., a Novartis Company Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Caravel Oculus
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.